Skip to main content

BioCardia, Inc.

BCDA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000925741

In the last 90 days, BioCardia, Inc. insiders filed 9 open-market purchases and 0 sales; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.65M in total; no superinvestor holds it.

Key figures

Insider buysLast 90 days, $30.1K in total
9
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +3 vs. previous quarter
21
13F valueReported value at the end of Q2 2026
$1.65M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding BCDA, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding BCDA at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by BioCardia, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 23, 2026 (view filing)8:14 PM ETSep 23Same dayAltman PeterPresident and CEOPPurchase+1.90K$1.05+$2.00K+0.5%383.9K after
Sep 4, 2026 (view filing)9:30 PM ETSep 31 dayAltman PeterPresident and CEOPPurchase+800$1.09+$872+0.2%382.0K after
Aug 18, 2026 (view filing)12:14 PM ETAug 171 dayAltman PeterPresident and CEOPPurchase+5.40K$0.93+$5.02K+1.4%381.1K after
Aug 13, 2026 (view filing)5:43 PM ETAug 13Same dayAltman PeterPresident and CEOPPurchase+1.90K$0.92+$1.75K+0.5%375.8K after
Jul 29, 2026 (view filing)9:05 PM ETJul 29Same dayAltman PeterPresident and CEOPPurchase+5.00K$0.78+$3.90K+1.4%373.9K after
Jul 20, 2026 (view filing)4:16 PM ETJul 173 daysAltman PeterPresident and CEOPPurchase+500$0.83+$415+0.1%368.9K after
Jul 15, 2026 (view filing)4:40 PM ETJul 14-151 dayAltman PeterPresident and CEOPPurchase+4.30K$0.873+$3.75K+1.2%368.4K after2 lots
Jul 10, 2026 (view filing)6:18 PM ETJul 8-102 daysAltman PeterPresident and CEOPPurchase+7.50K$0.9567+$7.17K+2.1%369.5K after3 lots
Jul 8, 2026 (view filing)3:30 PM ETJul 8Same dayAltman PeterPresident and CEOPPurchase+5.40K$0.9645+$5.21K+1.5%362.0K after
Jun 24, 2026 (view filing)Jun 22-232 daysStertzer Simon HDirectorPPurchase+109.2K$0.9486+$103.6K+191.1%166.3K after2 lots

Top 10 13F holders, Q2 2026

The largest institutional positions in BioCardia, Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 21 holders
Institutions holding BCDA in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Citigroup Inc397,594$493.0K0.00%+397,594New
CM Management, LLC300,000$372.0K0.24%+170,000+130.8%Added
Vanguard Capital Management LLC124,591$154.5K0.00%00.0%Unchanged
Pingora Partners LLC120,382$149.3K0.09%+84,643+236.8%Added
UBS Group AG77,619$96.2K0.00%+77,619New
Geode Capital Management, LLC66,664$82.7K0.00%−27,623−29.3%Reduced
Vanguard Fiduciary Trust Co66,270$82.2K0.00%00.0%Unchanged
Susquehanna International Group, LLP38,809$48.1K0.00%−180.0%Reduced
Brown Advisory Inc35,538$44.1K0.00%00.0%Unchanged
Commonwealth Equity Services, LLC23,383$29.0K0.00%+5,100+27.9%Added